Adapting the drivers to the road: a new strategy for cancer evolution?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.Neuro-oncology practice · 2026
   Article
2. A richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach.Journal of thoracic disease · 2018
   Article
3. Glioblastoma targeted therapy: updated approaches from recent biological insights.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
   Review

Corrections and comments

• Comment on
  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.2012

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as